610 Medizin und Gesundheit
Refine
Year of publication
- 2013 (350) (remove)
Document Type
- Article (265)
- Doctoral Thesis (34)
- Conference Proceeding (14)
- Part of Periodical (14)
- Contribution to a Periodical (12)
- Book (3)
- Review (3)
- Part of a Book (2)
- Periodical (2)
- Preprint (1)
Is part of the Bibliography
- no (350)
Keywords
- Video (19)
- Capsule endoscopy (12)
- Small bowel (10)
- Endoscopy (7)
- Balloon enteroscopy (6)
- Enteroscopy (6)
- Endoscopic retrograde cholangiopancreatography (4)
- Apoptosis (3)
- IAP proteins (3)
- Smac (3)
- epigenetics (3)
- Atrial fibrillation (2)
- Begriff (2)
- Begriffsgeschichte <Fach> (2)
- Bile duct stone (2)
- Blog (2)
- Breast cancer (2)
- CBA (2)
- COPD (2)
- Cholangiography (2)
- Cholangiopancreatography (2)
- Colonoscopy (2)
- Colorectal cancer (2)
- Double-balloon enteroscopy (2)
- Endoscopic retrograde (2)
- Enterscopy (2)
- Extended donor criteria (2)
- Gesichtsauflösung (2)
- Hemorrhage (2)
- Herb induced liver injury (2)
- IL-6 (2)
- KGF (2)
- Lymphectasia (2)
- Migration (2)
- PDGFRβ (2)
- ROS (2)
- Rhabdomyosarcoma (2)
- SD-OCT (2)
- Sestrin 2 (2)
- Social Media (2)
- Standard endoscopy (2)
- Stroke (2)
- Thrombolysis (2)
- VEGF (2)
- Web 2.0 (2)
- apoptosis (2)
- cardiac (2)
- cell death (2)
- gamma (2)
- glioblastoma (2)
- immunotherapy (2)
- leukemia (2)
- radiotherapy (2)
- schizophrenia (2)
- signal transduction (2)
- synchrony (2)
- therapy (2)
- ALL (1)
- AML (1)
- Actin (1)
- Adenocarcinoma (1)
- Adhesion (1)
- Adolescence (1)
- Airways (1)
- Allergy (1)
- Angiectasia (1)
- Angiodysplasia (1)
- Antibiotic generic drugs (1)
- Anticoagulation (1)
- Antifungal agents (1)
- Antineoplastic agents (1)
- Antiretrovirals (1)
- Antiviral therapy (1)
- Aortic debranching (1)
- Aortic dissection (1)
- Aromatase inhibitors (1)
- Arteriovenous malformation (1)
- Aspergillosis (1)
- Assessment (1)
- Asthma (1)
- Augenheilkunde (1)
- Augenverletzungen (1)
- Auric nanoparticles (1)
- Autism spectrum disorder (1)
- B-cell (1)
- B16 cells (1)
- BCL2 (1)
- BCR-ABL (1)
- BRVO (1)
- Ballet (1)
- Ballon-assisted enteroscopy (1)
- Bcl-2 (1)
- Befindlichkeit (1)
- Benign disorder (1)
- Bevacizumab (1)
- Bewältigung (1)
- Bildnis (1)
- Billroth II gastroenterostomy (1)
- Billroth papillotome (1)
- Billroth’s operation-II (1)
- Blood-brain barrier (1)
- Bortezomib (1)
- Brain (1)
- Brain development (1)
- Brain repair (1)
- Burnout-Syndrom (1)
- C1-inhibitor deficiency (1)
- CIOMS (1)
- CRVO (1)
- CXCL12 (1)
- CXCR4 (1)
- Cancer (1)
- Cancer stem cells (1)
- Candida (1)
- Capecitabine (1)
- Capsule endoscopy, video (1)
- Cardiac surgery (1)
- Castleman’s disease (1)
- Catheter ablation (1)
- Celiac disease (1)
- Cell Death (1)
- Cell Signaling (1)
- Cell Surface Receptor (1)
- Cellular Immune Response (1)
- Cerasorb (1)
- Cerebral Vasospasm (1)
- Chemoradiotherapy (1)
- Chronic illness (1)
- Chronic obstructive airway disease (1)
- Clip (1)
- Cohort study (1)
- Communication (1)
- Comparative study (1)
- Coordination Of Control Modes (1)
- Core needle biopsy (1)
- Coronary artery disease (CAD) (1)
- Cost And Quality Management (1)
- Crohn’s disease (1)
- Cryoablation (1)
- Cyanoacrylate (1)
- Cytochrome P450 (1)
- Cytokine (1)
- Cytotoxicity (1)
- DNA Adducts (1)
- DR5 (1)
- Dancer (1)
- Delayed Cerebral Ischemia (1)
- Dentin adhesives (1)
- Dermatologie (1)
- Device (1)
- Diabetic nephropathy (1)
- Dieulafoy’s lesion (1)
- Digestive system (1)
- Dilated cardiomyopathy (1)
- Disease management (1)
- Docetaxel (1)
- Doctors In Management (1)
- Double balloon enteroscopy (1)
- Doubling time (1)
- Drug Therapy (1)
- Drug hepatotoxicity (1)
- Drug induced liver injury (1)
- Duodenum (1)
- EEG (1)
- EWS/Fli1 (1)
- Ectopic bone formation (1)
- Ectopic varices (1)
- Effectivity (1)
- Elderly (1)
- Ellipticine (1)
- Endomicroscopy (1)
- Endoscopic papillotomy (1)
- Endoscopic retrograde cholangiography (1)
- Endoscopic sphincterotomy (1)
- Endoscopic treatment (1)
- Endoscopic ultrasound (1)
- Energieumsatz <Medizin> (1)
- Entzündung (1)
- Erschöpfung (1)
- Esophagogastric (1)
- Europe (1)
- European Comparison (1)
- Ewing sarcoma (1)
- Exemestane (1)
- FAP (1)
- FTY720 (1)
- Facet joint osteoarthritis (1)
- Fast-track (1)
- Female (1)
- Fever (1)
- Fibrinolytic (1)
- Fingolimod (1)
- G-CSF (1)
- Gastric adenoma (1)
- Gastric cancer (1)
- Gastritis (1)
- Gastrointestinal bleeding (1)
- Gene polymorphism (1)
- Generic drugs (1)
- Gesicht (1)
- Gesicht <Motiv> (1)
- Gewebedurchblutung (1)
- Gewebetemperatur (1)
- Giant lymph node hyperplasia (1)
- Glivec® (1)
- Glomerulonephritis (1)
- Gold (1)
- Graft function (1)
- Graft survival (1)
- Graz <2013> (1)
- HAE (1)
- HDACi (1)
- HIV therapy (1)
- HNPCC (1)
- HSPC (1)
- Heart (1)
- Hebbian plasticity (1)
- Hematologic malignancies (1)
- Hemobilia (1)
- Hepatitis C (1)
- Herbalife products (1)
- Hexavalent vaccine (1)
- Hormonal (1)
- Hospital Governance (1)
- Hydroxyapatite (1)
- ICU (1)
- IMiD® (1)
- ISO (1)
- Identity (1)
- Identität (1)
- Immunology (1)
- In-vivo (1)
- Infektionsabwehr (1)
- Infektionskrankheit (1)
- Inflammatory bowel disease (1)
- Inflammatory fibroid polyp (1)
- Infrarot (1)
- Innate Immunity (1)
- Innate immunity (1)
- Integrin (1)
- Intestinal fistula (1)
- Intestinal metaplasia (1)
- Intestinal neoplasms (1)
- Invasive candidiasis (1)
- Ischemia (1)
- Ischemia-reperfusion injury (1)
- Kava (1)
- Kidney disease (1)
- Kinderwunsch (1)
- Kommunikation (1)
- Kongress (1)
- Krankheit (1)
- Krankheitsbegriff (1)
- Künste (1)
- Landmark (1)
- Langerhans cell histiocytosis (1)
- Lebensbewältigung (1)
- Lebensgefühl (1)
- Liver biopsy (1)
- Liver histology (1)
- Liver injury (1)
- Liver transplantation (1)
- Lumbar stenosis (1)
- Lung (1)
- Lymphangiectasia (1)
- Lymphoepithelioma (1)
- Lymphoma (1)
- MACE (1)
- MCAO (1)
- MCP (1)
- MCP-1 (1)
- MEG (1)
- MLL (1)
- MTCL (1)
- MTT (1)
- Male (1)
- Marginal grafts (1)
- Medizin (1)
- Medizinische Ausbildung (1)
- Mena/VASP (1)
- Metal clip (1)
- Metapher (1)
- Metastatic (1)
- Mid-intestinal bleeding (1)
- Minimally invasive transforaminal interbody fusion (1)
- Missbildung (1)
- Moderating factors (1)
- Multiple trauma (1)
- Mund-Kiefer-Gesichts-Chirurgie (1)
- Mycoses (1)
- NF-κB (1)
- NK Receptor (1)
- NK cell (1)
- NS3-4A protease inhibitor (1)
- NS5B polymerase inhibitor (1)
- NanoBone (1)
- Nanocrystalline (1)
- Natural Killer (NK) Cell (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant treatment (1)
- Nerven <Begriff> (1)
- Neural function (1)
- Neural stem cells (1)
- Neurasthenie (1)
- Neuroendocrine tumor (1)
- Neurogenesis (1)
- Neurotransmitter (1)
- New Developments (1)
- Nicht-Ereignis (1)
- Non-Hodgkin lymphoma (1)
- Occupational disease (1)
- Occupational exposure (1)
- Occupational health (1)
- Oesophagogastric cancer oxaliplatin (1)
- Off-pump surgery (1)
- Oncolytic virus (1)
- Oncotargets (1)
- Online-Magazin (1)
- Online-Magazine (1)
- Organ allocation (1)
- Organ rinse (1)
- Organ shortage (1)
- Osteoinduction (1)
- Osteoporosis (1)
- Outcome (1)
- Over-the-scope clip (1)
- Oxaliplatin (1)
- PAX3/FOXO1 (1)
- PET (1)
- Pancreas transplantation (1)
- Paracetamol (1)
- Paraneoplastic syndrome (1)
- Pathologic complete response (1)
- Pelargonium sidoides (1)
- Percutaneous ultrasound (1)
- Peroxidase (1)
- Personality disorder (1)
- Peutz–Jeghers syndrome (1)
- Pharmacodynamic (1)
- Philosophie (1)
- Physical therapist (1)
- Planning target volume (1)
- Platelets (1)
- Pneumococcal conjugate vaccine (1)
- Polyposis syndrome (1)
- Postoperative anatomy (1)
- Preoperative radiochemotherapy (1)
- Professionalism (1)
- Prophylaxis (1)
- Protein Expression (1)
- Psychopathology (1)
- Pulmonary failure (1)
- Pulmonary veins (1)
- Qualitative research (1)
- RAD001 (1)
- RIP1 (1)
- RNA interference (RNAi) (1)
- RUNX1/ETO (1)
- Radiation induced diarrhoea (1)
- Radiotherapy (1)
- Rare disease (1)
- Readmission (1)
- Rectal cancer (1)
- Rejection (1)
- Religiöses Coping (1)
- Restenosis (1)
- S1P1 receptor (1)
- SERS (1)
- SOCS (1)
- Sauerstoffpartialdruck im Gewebe (1)
- Sauerstoffversorgung (1)
- Schmerz (1)
- Schmerzminderung (1)
- Sekretion (1)
- Selenium administration in gynecologic radiation oncology (1)
- Self-expandable metal stents (1)
- Self-expandable metal stents complications (1)
- Self-management support (1)
- Signaling (1)
- Small-bowel endoscopy (1)
- Social skills training (1)
- Spectrin (1)
- Sphingolipid (1)
- Sphingosine 1-phosphate (1)
- Spondylolisthesis (1)
- Sportmedizin (1)
- Sportophthalmologie (1)
- Sportärztekongress (1)
- Stentoplasty (1)
- Study protocol (1)
- Subacute cerebellar degeneration (1)
- Subarachnoid Hemorrhage (1)
- Subfertilität (1)
- Supraventricular arrhythmias (1)
- Syk Kinase (1)
- T cell (1)
- T-cell homeostasis (1)
- T-cell niche (1)
- TEM (1)
- TEVAR (1)
- TKI (1)
- TRAIL (1)
- Tacrolimus (1)
- Tamoxifen (1)
- Temozolomide (1)
- Terminal ileitis (1)
- Thalidomide (1)
- Thoracic trauma (1)
- Thyroid Cancer Cells (1)
- Toll-like receptor (TLR) 6 (1)
- Tonsil (1)
- Toxicology (1)
- Toxins (1)
- Traumatic injury (1)
- Treatment (1)
- Tumor (1)
- Tumor obstruction (1)
- Tumor subtype (1)
- Ultrasonography (1)
- Unfallverletzung (1)
- Ungewollte Kinderlosigkeit (1)
- VEGF receptors (1)
- VIP (1)
- VPAC1 (1)
- Variceal bleeding (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Virotherapy (1)
- Vitreous samples (1)
- Western Blotting (1)
- Wilms tumor (1)
- Wissenschaft (1)
- Wunde (1)
- Wundheilung (1)
- Wundinfektion (1)
- YB-1 (1)
- Zivilisationskrankheit (1)
- active perception (1)
- acute leukemia (1)
- acute lymphoblastic leukaemia (1)
- acute myeloid leukaemia (1)
- ageing (1)
- aging (1)
- air pouch (1)
- all-ceramic (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alpha peak (1)
- antifungal agents (1)
- antifungal management (1)
- antifungal prophylaxis (1)
- astrocyte (1)
- astrocytes (1)
- atherosclerosis (1)
- attention (1)
- barriers to implementation (1)
- biocompatibility (1)
- bone morphogenetic protein-2 (1)
- bone substitute material (1)
- bortezomib (1)
- brain injury (1)
- cancer (1)
- cardiovascular (1)
- cardiovascular disease (1)
- chemotherapy (1)
- childhood cancer (1)
- chromosomal translocations (1)
- chronic care (1)
- cigarette (1)
- clinical research (1)
- clinical study (1)
- clinical trials (1)
- cochlear implant (1)
- cognition (1)
- consciousness (1)
- corticomuscular coherence (CMC) (1)
- costs (1)
- crestal bone loss (1)
- critical periods (1)
- crowns (1)
- deconvolution (1)
- development (1)
- directly acting antiviral agents (1)
- distraction (1)
- dual task (1)
- endothelial (1)
- entorhinal cortex lesion (1)
- everolimus (1)
- exercise (1)
- expert review (1)
- fMRI (1)
- finger tapping (1)
- functional MRI (1)
- fungal infection (1)
- gastric (1)
- gastrointestinal (1)
- gene therapy (1)
- glutamate metabolism (1)
- granulocyte (1)
- growth factor (1)
- hand area (1)
- head and neck cancer (1)
- hematopoietic stem and progenitor cells (1)
- hemodialysis (1)
- hepatitis C virus (1)
- hereditary angioedema (1)
- hippocampal volume (1)
- homeostatic synaptic scaling (1)
- iPS (1)
- immune function (1)
- immunocytochemistry (1)
- immunology (1)
- implant (1)
- implant survival (1)
- inflammation (1)
- inhibition of DNA-binding (1)
- interferon-free (1)
- interleukin-10 (1)
- interleukin-22 (1)
- invasive fungal infection (1)
- kidney disease (1)
- lenalidomide (1)
- long-term survival (1)
- mTOR (1)
- magnetoencephalography (1)
- magnetoencephalography (MEG) (1)
- marginal bone loss (1)
- mature T-cell lymphoma (1)
- memory (1)
- metaplasticity (1)
- miRNA (1)
- miRNA-17–92 (1)
- microRNA (1)
- mild cognitive impairment (1)
- mitogen-activated protein kinase (1)
- mitomycin C (1)
- mobilization (1)
- monogenic disorders (1)
- motor control (1)
- motor task (1)
- nanoparticles (1)
- natural killer cell (1)
- necroptosis (1)
- neurobiology (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurological diseases (1)
- neurooncology (1)
- neuropsychiatric disorders (1)
- next-generation sequencing (1)
- non-invasive brain stimulation (1)
- oligodendrocyte (1)
- organotypic slice cultures (1)
- oscillations (1)
- oxidative stress (1)
- pain (1)
- peptide aptamer (PA) (1)
- perceptual organization (1)
- plasticity (1)
- posaconazole (1)
- pregnancy (1)
- pregnant (1)
- preprocedure prophylaxis (1)
- prevention (1)
- primary motor cortex (1)
- primary motor cortex (M1) (1)
- prognostic value (1)
- progranulin (1)
- prostate and breast cancer cell lines (1)
- prostate cancer (1)
- proteasome inhibitor (1)
- protein transduction (1)
- rat femur defect (1)
- receptor tyrosine kinase (1)
- reduction of pain (1)
- reinforcement learning (1)
- resting state (1)
- robotics (1)
- robustness (1)
- scaffolding proteins (1)
- sciatic nerve injury (1)
- self-management support (1)
- senescence (1)
- signal transducer and activator of transcription (1)
- signal transducer and activator of transcription 5 (Stat5) (1)
- signaling (1)
- single-sided deafness (1)
- sleep (1)
- slowing (1)
- smoking (1)
- sonic hedgehog (1)
- sparse coding (1)
- stem cell therapy (1)
- stem/progenitor cell expansion (1)
- stereo vision (1)
- structural plasticity (1)
- surgical procedures (1)
- survival rate (1)
- thalidomide (1)
- therapeutics (1)
- three point bending test (1)
- tissue blood flow (1)
- tissue oxygen partial pressure (1)
- tissue temperature (1)
- tobacco (1)
- tooth wear (1)
- toxicity (1)
- transcranial alternating current stimulation (tACS) (1)
- translocation partner genes (1)
- tricalcium phosphate (1)
- tumour-infiltrating lymphocytes (1)
- type I interferons (1)
- vascular (1)
- vergence (1)
- viral vectors (1)
- vitreous samples (1)
- wIRA (1)
- wassergefiltertes Infrarot A (1)
- water-filtered infrared-A (wIRA) (1)
- yeast-two-hybrid (Y2H) (1)
- Ätiologie (1)
- ß-tricalciumphosphate (1)
Institute
Surfactant proteins (SP) have been studied intensively in the respiratory system. Surfactant protein A and surfactant protein D are proteins belonging to the family of collectins each playing a major role in the innate immune system. The ability of surfactant protein A and surfactant protein D to bind various pathogens and facilitate their elimination has been described in a vast number of studies. Surfactant proteins are very important in modulating the host's inflammatory response and participate in the clearance of apoptotic cells. Surfactant protein B and surfactant protein C are proteins responsible for lowering the surface tension in the lungs. The aim of this study was an investigation of expression of surfactant proteins in the central nervous system to assess their specific distribution patterns. The second aim was to quantify surfactant proteins in cerebrospinal fluid of healthy subjects compared to patients suffering from different neuropathologies. The expression of mRNA for the surfactant proteins was analyzed with RT-PCR done with samples from different parts of the human brain. The production of the surfactant proteins in the brain was verified using immunohistochemistry and Western blot. The concentrations of the surfactant proteins in cerebrospinal fluid from healthy subjects and patients suffering from neuropathologic conditions were quantified using ELISA. Our results revealed that surfactant proteins are present in the central nervous system and that the concentrations of one or more surfactant proteins in healthy subjects differed significantly from those of patients affected by central autoimmune processes, CNS infections or cerebral infarction. Based on the localization of the surfactant proteins in the brain, their different levels in normal versus pathologic samples of cerebrospinal fluid and their well-known functions in the lungs, it appears that the surfactant proteins may play roles in host defense of the brain, facilitation of cerebrospinal fluid secretion and maintenance of the latter's rheological properties.
The effect of 10 Hz transcranial alternating current stimulation (tACS) on corticomuscular coherence
(2013)
Synchronous oscillatory activity at alpha (8–12 Hz), beta (13–30 Hz), and gamma (30–90 Hz) frequencies is assumed to play a key role for motor control. Corticomuscular coherence (CMC) represents an established measure of the pyramidal system's integrity. Transcranial alternating current stimulation (tACS) offers the possibility to modulate ongoing oscillatory activity. Behaviorally, 20 Hz tACS in healthy subjects has been shown to result in movement slowing. However, the neurophysiological changes underlying these effects are not entirely understood yet. The present study aimed at ascertaining the effects of tACS at 10 and 20 Hz in healthy subjects on CMC and local power of the primary sensorimotor cortex. Neuromagnetic activity was recorded during isometric contraction before and at two time points (2–10 min and 30–38 min) after tACS of the left primary motor cortex (M1), using a 306 channel whole head magnetoencephalography (MEG) system. Additionally, electromyography (EMG) of the right extensor digitorum communis (EDC) muscle was measured. TACS was applied at 10 and 20 Hz, respectively, for 10 min at 1 mA. Sham stimulation served as control condition. The data suggest that 10 Hz tACS significantly reduced low gamma band CMC during isometric contraction. This implies that tACS does not necessarily cause effects at stimulation frequency. Rather, the findings suggest cross-frequency interplay between alpha and low gamma band activity modulating functional interaction between motor cortex and muscle.
Over the last century, humans from industrialized societies have witnessed a radical increase in some dental diseases. A severe problem concerns the loss of dental materials (enamel and dentine) at the buccal cervical region of the tooth. This “modern-day” pathology, called non-carious cervical lesions (NCCLs), is ubiquitous and worldwide spread, but is very sporadic in modern humans from pre-industrialized societies. Scholars believe that several factors are involved, but the real dynamics behind this pathology are far from being understood. Here we use an engineering approach, finite element analysis (FEA), to suggest that the lack of dental wear, characteristic of industrialized societies, might be a major factor leading to NCCLs. Occlusal loads were applied to high resolution finite element models of lower second premolars (P2) to demonstrate that slightly worn P2s envisage high tensile stresses in the buccal cervical region, but when worn down artificially in the laboratory the pattern of stress distribution changes and the tensile stresses decrease, matching the results obtained in naturally worn P2s. In the modern industrialized world, individuals at advanced ages show very moderate dental wear when compared to past societies, and teeth are exposed to high tensile stresses at the buccal cervical region for decades longer. This is the most likely mechanism explaining enamel loss in the cervical region, and may favor the activity of other disruptive processes such as biocorrosion. Because of the lack of dental abrasion, our masticatory apparatus faces new challenges that can only be understood in an evolutionary perspective.
Background: Group-based social skills training (SST) has repeatedly been recommended as treatment of choice in high-functioning autism spectrum disorder (HFASD). To date, no sufficiently powered randomised controlled trial has been performed to establish efficacy and safety of SST in children and adolescents with HFASD. In this randomised, multi-centre, controlled trial with 220 children and adolescents with HFASD it is hypothesized, that add-on group-based SST using the 12 weeks manualised SOSTA–FRA program will result in improved social responsiveness (measured by the parent rated social responsiveness scale, SRS) compared to treatment as usual (TAU). It is further expected, that parent and self reported anxiety and depressive symptoms will decline and pro-social behaviour will increase in the treatment group. A neurophysiological study in the Frankfurt HFASD subgroup will be performed pre- and post treatment to assess changes in neural function induced by SST versus TAU.
Methods/design: The SOSTA – net trial is designed as a prospective, randomised, multi-centre, controlled trial with two parallel groups. The primary outcome is change in SRS score directly after the intervention and at 3 months follow-up. Several secondary outcome measures are also obtained. The target sample consists of 220 individuals with ASD, included at the six study centres.
Discussion: This study is currently one of the largest trials on SST in children and adolescents with HFASD worldwide. Compared to recent randomised controlled studies, our study shows several advantages with regard to in- and exclusion criteria, study methods, and the therapeutic approach chosen, which can be easily implemented in non-university-based clinical settings.
Trial registration: ISRCTN94863788 – SOSTA – net: Group-based social skills training in children and adolescents with high functioning autism spectrum disorder.
The signal transducer and activator of transcription Stat5 is transiently activated by growth factor and cytokine signals in normal cells, but its persistent activation has been observed in a wide range of human tumors. Aberrant Stat5 activity was initially observed in leukemias, but subsequently also found in carcinomas. We investigated the importance of Stat5 in human tumor cell lines. shRNA mediated downregulation of Stat5 revealed the dependence of prostate and breast cancer cells on the expression of this transcription factor. We extended these inhibition studies and derived a peptide aptamer (PA) ligand, which directly interacts with the DNA-binding domain of Stat5 in a yeast-two-hybrid screen. The Stat5 specific PA sequence is embedded in a thioredoxin (hTRX) scaffold protein. The resulting recombinant protein S5-DBD-PA was expressed in bacteria, purified and introduced into tumor cells by protein transduction. Alternatively, S5-DBD-PA was expressed in the tumor cells after infection with a S5-DBD-PA encoding gene transfer vector. Both strategies impaired the DNA-binding ability of Stat5, suppressed Stat5 dependent transactivation and caused its intracellular degradation. Our experiments describe a peptide based inhibitor of Stat5 protein activity which can serve as a lead for the development of a clinically useful compound for cancer treatment.
Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize the chromosomal rearrangement of individual acute leukemia patients. We present data of the molecular characterization of 1590 MLL-rearranged biopsy samples obtained from acute leukemia patients. The precise localization of genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and novel TPGs identified. All patients were classified according to their gender (852 females and 745 males), age at diagnosis (558 infant, 416 pediatric and 616 adult leukemia patients) and other clinical criteria. Combined data of our study and recently published data revealed a total of 121 different MLL rearrangements, of which 79 TPGs are now characterized at the molecular level. However, only seven rearrangements seem to be predominantly associated with illegitimate recombinations of the MLL gene (~ 90%): AFF1/AF4, MLLT3/AF9, MLLT1/ENL, MLLT10/AF10, ELL, partial tandem duplications (MLL PTDs) and MLLT4/AF6, respectively. The MLL breakpoint distributions for all clinical relevant subtypes (gender, disease type, age at diagnosis, reciprocal, complex and therapy-induced translocations) are presented. Finally, we present the extending network of reciprocal MLL fusions deriving from complex rearrangements.
Mobilized blood has supplanted bone marrow (BM) as the primary source of hematopoietic stem cells for autologous and allogeneic stem cell transplantation. Pharmacologically enforced egress of hematopoietic stem cells from BM, or mobilization, has been achieved by directly or indirectly targeting the CXCL12/CXCR4 axis. Shortcomings of the standard mobilizing agent, granulocyte colony-stimulating factor (G-CSF), administered alone or in combination with the only approved CXCR4 antagonist, Plerixafor, continue to fuel the quest for new mobilizing agents. Using Protein Epitope Mimetics technology, a novel peptidic CXCR4 antagonist, POL5551, was developed. In vitro data presented herein indicate high affinity to and specificity for CXCR4. POL5551 exhibited rapid mobilization kinetics and unprecedented efficiency in C57BL/6 mice, exceeding that of Plerixafor and at higher doses also of G-CSF. POL5551-mobilized stem cells demonstrated adequate transplantation properties. In contrast to G-CSF, POL5551 did not induce major morphological changes in the BM of mice. Moreover, we provide evidence of direct POL5551 binding to hematopoietic stem and progenitor cells (HSPCs) in vivo, strengthening the hypothesis that CXCR4 antagonists mediate mobilization by direct targeting of HSPCs. In summary, POL5551 is a potent mobilizing agent for HSPCs in mice with promising therapeutic potential if these data can be orroborated in humans.
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients. Treatment algorithms for the management of common ipilimumab-induced AEs have lead to a reduction of morbidity, e.g. due to bowel perforations. However, the spectrum of less common AEs is expanding as ipilimumab is increasingly applied. Stringent recognition and management of AEs will reduce drug-induced morbidity and costs, and thus, positively impact the cost-benefit ratio of the drug. To facilitate timely identification and adequate management data on rare AEs were analyzed at 19 skin cancer centers.
Methods and Findings: Patient files (n = 752) were screened for rare ipilimumab-associated AEs. A total of 120 AEs, some of which were life-threatening or even fatal, were reported and summarized by organ system describing the most instructive cases in detail. Previously unreported AEs like drug rash with eosinophilia and systemic symptoms (DRESS), granulomatous inflammation of the central nervous system, and aseptic meningitis, were documented. Obstacles included patientś delay in reporting symptoms and the differentiation of steroid-induced from ipilimumab-induced AEs under steroid treatment. Importantly, response rate was high in this patient population with tumor regression in 30.9% and a tumor control rate of 61.8% in stage IV melanoma patients despite the fact that some patients received only two of four recommended ipilimumab infusions. This suggests that ipilimumab-induced antitumor responses can have an early onset and that severe autoimmune reactions may reflect overtreatment.
Conclusion: The wide spectrum of ipilimumab-induced AEs demands doctor and patient awareness to reduce morbidity and treatment costs and true ipilimumab success is dictated by both objective tumor responses and controlling severe side effects.
Transcription factors play a crucial role in regulating differentiation processes during human life and are important in disease. The basic helix-loop-helix transcription factors Tal1 and Lyl1 play a major role in the regulation of gene expression in the hematopoietic system and are involved in human leukemia. Tal2, which belongs to the same family of transcription factors as Tal1 and Lyl1, is also involved in human leukaemia. However, little is known regarding the expression and regulation of Tal2 in hematopoietic cells. Here we show that Tal2 is expressed in hematopoietic cells of the myeloid lineage. Interestingly, we found that usage of the Tal2 promoter is different in human and mouse cells. Two promoters, hP1 and hP2 drive Tal2 expression in human erythroleukemia K562 cells, however in mouse RAW cells only the mP1 promoter is used. Furthermore, we found that Tal2 expression is upregulated during oesteoclastogenesis. We show that Tal2 is a direct target gene of the myeloid transcription factor PU.1, which is a key transcription factor for osteoclast gene expression. Strikingly, PU.1 binding to the P1 promoter is conserved between mouse and human, but PU.1 binding to P2 was only detected in human K562 cells. Additionally, we provide evidence that Tal2 influences the expression of the osteoclastic differentiation gene TRACP. These findings provide novel insight into the expression control of Tal2 in hematopoietic cells and reveal a function of Tal2 as a regulator of gene expression during osteoclast differentiation.
Background and study objective: Focused lung ultrasound (LUS) examinations are important tools in critical care medicine. There is evidence that LUS can be used for the detection of acute thoracic lesions. However, no validated training method is available. The goal of this study was to develop and assess an objective structured clinical examination (OSCE) curriculum for focused thorax, trachea, and lung ultrasound in emergency and critical care medicine (THOLUUSE).
Methods: 39 trainees underwent a one-day training course in a prospective educational study, including lectures in sonoanatomy and -pathology of the thorax, case presentations, and hands-on training. Trainees' pre- and posttest performances were assessed by multiple choice questionnaires, visual perception tests by interpretation video clips, practical performance of LUS, and identification of specific ultrasound findings.
Results: Trainees postcourse scores of correct MCQ answers increased from 56 ± 4% to 82 ± 2% (mean± SD; P < 0.001); visual perception skills increased from 54 ± 5% to 78 ± 3% (P < 0.001); practical ultrasound skills improved, and correct LUS was performed in 94%. Subgroup analysis revealed that learning success was independent from the trainees' previous ultrasound experience.
Conclusions: THOLUUSE significantly improves theoretical and practical skills for the diagnosis of acute thoracic lesions. We propose to implement THOLUUSE in emergency medicine training.
We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.). Coagulation parameters were normal (thrombin time 20 s, aPTT 20 s, INR 1.08) and the patient improved from an NIHSS of 15 to 5 within 24 h with sonographic evidence of M1 recanalization. She did not develop intracranial bleeding complications but showed unusually large diffuse skin ecchymoses. In our report, we give an overview of all reported cases of thrombolysis under dabigatran anticoagulation and discuss the questions of medication adherence under novel oral anticoagulants (NOA) and the safety of NOA in terms of secondary intracerebral hemorrhage after stroke.
Objective: Loss of function mutations in PINK1 typically lead to early onset Parkinson disease (PD). Zebrafish (Danio rerio) are emerging as a powerful new vertebrate model to study neurodegenerative diseases. We used a pink1 mutant (pink−/−) zebrafish line with a premature stop mutation (Y431*) in the PINK1 kinase domain to identify molecular mechanisms leading to mitochondrial dysfunction and loss of dopaminergic neurons in PINK1 deficiency.
Methods: The effect of PINK1 deficiency on the number of dopaminergic neurons, mitochondrial function, and morphology was assessed in both zebrafish embryos and adults. Genome-wide gene expression studies were undertaken to identify novel pathogenic mechanisms. Functional experiments were carried out to further investigate the effect of PINK1 deficiency on early neurodevelopmental mechanisms and microglial activation.
Results: PINK1 deficiency results in loss of dopaminergic neurons as well as early impairment of mitochondrial function and morphology in Danio rerio. Expression of TigarB, the zebrafish orthologue of the human, TP53-induced glycolysis and apoptosis regulator TIGAR, was markedly increased in pink−/− larvae. Antisense-mediated inactivation of TigarB gave rise to complete normalization of mitochondrial function, with resulting rescue of dopaminergic neurons in pink−/− larvae. There was also marked microglial activation in pink−/− larvae, but depletion of microglia failed to rescue the dopaminergic neuron loss, arguing against microglial activation being a key factor in the pathogenesis.
Interpretation: Pink1−/− zebrafish are the first vertebrate model of PINK1 deficiency with loss of dopaminergic neurons. Our study also identifies TIGAR as a promising novel target for disease-modifying therapy in PINK1-related PD. Ann Neurol 2013;74:837–847
The objective of this systematic review was to assess tooth wear against ceramic crowns in posterior region in vitro and in vivo. An electronic PubMed search was conducted to identify studies on tooth wear against ceramic crowns in posterior region. The selected studies were analyzed in regard to type of crowns, natural antagonist, measuring protocol and outcome. From a yield of 1 000 titles, 43 articles were selected for full-text analysis; finally, no in vitro and only five in vivo studies met the inclusion criteria. As there is heterogeneity in design, used measuring method, ceramics and analysis-form, a meta-analysis was not possible. Results of these studies are very controversial which makes a scientifically valid comparison impossible. This review indicated that some all-ceramic crowns are as wear friendly as metal-ceramic crowns. Up to now, it has been impossible to associate tooth wear with any specific causal agent. The role of ceramic surface treatment that might be responsible for the changing in rate of tooth wear seems undetermined as yet through clinical trials. The literature reveals that studies on this topic are subject to a substantial amount of bias. Therefore, additional clinical studies, properly designed to diminish bias, are warranted.
Corneal scarring remains a major cause of blindness world-wide, with limited treatment options, all of which have side-effects. Here, we tested the hypothesis that topical application of Rosiglitazone, a Thiazolidinedione and ligand of peroxisome proliferator activated receptor gamma (PPARγ), can effectively block scar formation in a cat model of corneal damage. Adult cats underwent bilateral epithelial debridement followed by excimer laser ablation of the central corneal stroma to a depth of ~160 µm as a means of experimentally inducing a reproducible wound. Eyes were then left untreated, or received 50 µl of either 10 µM Rosiglitazone in DMSO/Celluvisc, DMSO/Celluvisc vehicle or Celluvisc vehicle twice daily for 2 weeks. Cellular aspects of corneal wound healing were evaluated with in vivo confocal imaging and post-mortem immunohistochemistry for alpha smooth muscle actin (αSMA). Impacts of the wound and treatments on optical quality were assessed using wavefront sensing and optical coherence tomography at 2, 4, 8 and 12 weeks post-operatively. In parallel, cat corneal fibroblasts were cultured to assess the effects of Rosiglitazone on TGFβ-induced αSMA expression. Topical application of Rosiglitazone to cat eyes after injury decreased αSMA expression and haze, as well as the induction of lower-order and residual, higher-order wavefront aberrations compared to vehicle-treated eyes. Rosiglitazone also inhibited TGFβ-induced αSMA expression in cultured corneal fibroblasts. In conclusion, Rosiglitazone effectively controlled corneal fibrosis in vivo and in vitro, while restoring corneal thickness and optics. Its topical application may represent an effective, new avenue for the prevention of corneal scarring with distinct advantages for pathologically thin corneas.
OBJECTIVE: Traffic crashes and related injuries are important causes of morbidity and mortality and impose insofar an important burden on public health. However, research in this area is often under-funded. The aim of this study was to analyse quantity, evolution and geographic distribution of traffic medicine-related research. This multi-sectorial field covers both transport and health care sectors.
DESIGN: A scientometric approach in combination with visualizing density equalizing mapping was used to analyse published data related to the field of traffic medicine between 1900 and 2008 within the "Web of Science" (WoS) database.
RESULTS: In total, 5,193 traffic medicine-associated items were produced between 1900 and 2008. The United States was found to have the highest research activity with a production of n = 2,330 published items, followed by Germany (n = 298) and Canada (n = 219). Cooperation analyses resulted in a peak of published multilateral cooperations in the year of 2003. The country with the highest multilateral activity was the USA. The average number of cited references per publication varied heavily over the last 20 years with a maximum of 27.67 in 1995 and a minimum of 15.08 in 1998. Also, a further in-depth analysis was performed with a focus solely on public health aspects which revealed similar trends.
CONCLUSIONS: Summarizing the present data it can be stated traffic medicine-related research productivity grows annually. Also, an active networking between countries is present. The data of the present study may be used by scientific organisations in order to gain detailed information about research activities in this field which is extremely important for public health.
Background: Tobacco is a leading environmental factor in the initiation of respiratory diseases and causes chronic obstructive pulmonary disease (COPD). Suppressor of cytokine signaling (SOCS) family members are involved in the pathogenesis of many inflammatory diseases and SOCS-3 has been shown to play an important role in the regulation, onset and maintenance of airway allergic inflammation indicating that SOCS-3 displays a potential therapeutic target for anti-inflammatory respiratory drugs development. Since chronic obstructive pulmonary disease (COPD) is also characterized by inflammatory changes and airflow limitation, the present study assessed the transcriptional expression of SOCS-3 in COPD.
Methods: Real-time PCR was performed to assess quantitative changes in bronchial biopsies of COPD patients in comparison to unaffected controls.
Results: SOCS-3 was significantly down-regulated in COPD at the transcriptional level while SOCS-4 and SOCS-5 displayed no change.
Conclusions: It can be concluded that the presently observed inhibition of SOCS-3 mRNA expression may be related to the dysbalance of cytokine signaling observed in COPD.
Background: High-producer TGFβ1 genotypes are associated with severe lung disease in cystic fibrosis (CF), but studies combining IL-8, TNFα-, and TGFβ1(+genotype) levels and their impact on CF lung disease are scarce.
Aim: Assessing the relationship between TGFβ1, IL-8, and TNF-α and lung disease in CF in an exacerbation-free interval.
Methods: Twenty four patients delta F508 homozygous (median age 20.5 y, Shwachman score 75, FEV1(%) 83) and 8 controls (median age 27.5 y) were examined. TGFβ1 was assessed in serum and induced sputum (IS) by ELISA, for IL-8 and TNF-α by chemiluminescence in IS and whole blood. Genotyping was performed for TGFβ1 C−509T and T+869C utilizing RFLP.
Results: TGFβ1 in IS (CF/controls median 76.5/59.1 pg/mL, P < 0.074) was higher in CF. There was a negative correlation between TGFβ1 in serum and lung function (LF) (FEV1 (r = −0.488, P = 0.025), MEF 25 (r = −0.425, P = 0.055), and VC (r = −0.572, P = 0.007)). Genotypes had no impact on TGFβ1 in IS, serum, and LF. In IS TGFβ1 correlated with IL-8 (r = 0.593, P < 0.007) and TNF-α (r = 0.536, P < 0.018) in patients colonized by bacteria with flagellin.
Conclusion: TGFβ1 in serum not in IS correlates with LF. In patients colonized by bacteria with flagellin, TGFβ1 correlates with IL-8 and TNF-α in IS.
Der ischämische Schlaganfall zählt zu den häufigsten Todesursachen in den Industrienationen und hinterlässt die meisten überlebenden Patienten in einer Pflegebedürftigkeit. Trotz der hohen Inzidenz und der gravierenden Folgen eines Schlaganfalls gibt es bislang keine ausreichende medikamentöse Therapie zum Schutz der Nervenzellen. Die akute Versorgung beschränkt sich auf die Lyse des Thrombus, welcher die betroffene Hirnarterie verschließt, und auf symptomatische Maßnahmen.
In der vorliegenden Dissertation wurden daher das neuroprotektiv wirkende Bilobalid, eine Substanz aus dem Ginkgo biloba Baum, und das anaplerotisch wirksame Triheptanoin auf ihre schützende Wirkung während eines ischämischen Schlaganfalls im Mausmodell untersucht. Zusätzlich wurden in der Bilobalid-Studie Tiere aus zwei verschiedenen Altersgruppen (6-8 Wochen gegen 18-24 Monate) verglichen. Der transiente Schlaganfall wurde in der Maus durch einstündigen Verschluss der mittleren Cerebralarterie (MCAO, middle cerebral artery occlusion) induziert.
Bilobalid wurde prophylaktisch eine Stunde vor Induktion des Schlaganfalls intraperitoneal (10 mg/kg) oder lokal in das betroffene Hirnareal (10 µM) verabreicht. Alle durchgeführten Experimente wiesen auf eine deutliche Neuroprotektion durch die Gabe von Bilobalid hin. Ein Tag nach MCAO war die Infarktfläche durch die Gabe von Bilobalid signifikant vermindert. In den durchgeführten motorischen Verhaltenstests schnitten die Bilobalid-behandelten Tiere wesentlich besser ab als unbehandelte Tiere. Der beobachtete Schutzeffekt von Bilobalid wurde auf mitochondriale Prozesse zurückgeführt: Die nach Ischämie beobachteten Defizite in Komplex I der mitochondrialen Atmungskette wurden durch die Gabe von Bilobalid deutlich vermindert. Bilobalid verringerte außerdem den enormen Anstieg von extrazellulärem Glutamat und das Ausmaß der mitochondrialen Schwellung während MCAO.
In der Altersstudie wurde deutlich, dass sowohl die motorische Aktivität der Tiere als auch einige zelluläre Prozesse wie die mitochondriale Atmung beeinträchtigt sind. Nichtsdestotrotz zeigte Bilobalid auch in gealterten Tieren einen deutlichen protektiven Effekt nach Ischämie.
Das anaplerotisch wirksame Triheptanoin wurde den Mäusen in einer 14-tätigen Fütterungsstudie verabreicht (33 % der Gesamt-Kalorien). Deutliche Schutzeffekte der Triheptanoin-Diät wurden nach Ischämie sowohl in TTC-gefärbten Hirnschnitten als auch in motorischen Verhaltenstests beobachtet. Durch den anaplerotischen Effekt sollte einerseits der Citratcyclus mit Acetyl-CoA und Succinyl-CoA gespeist werden, andererseits könnte Succinat in Komplex II der Atmungskette als direkter Energielieferant dienen. Dieser theoretische Ansatz wurde experimentell bestätigt: Die Fütterung mit Triheptanoin bewirkte eine signifikante Aktivitätssteigerung der mitochondrialen Komplexe II und IV nach MCAO. Die durch Ischämie gesenkten ATP-Spiegel und das Membranpotential wurden durch die anaplerotische Diät ebenfalls deutlich erhöht. Triheptanoin bewirkte zudem eine signifikante Reduktion des extrazellulären Glutamat-Anstiegs wŠhrend der MCAO.
Die Auswirkungen eines Schlaganfalls wurden demnach sowohl durch die prophylaktische Gabe von Bilobalid eine Stunde vor Ischämie als auch durch die 14-tägige Triheptanoin-Diät maßgeblich vermindert. Beide Substanzen zeigten im Mausmodell bemerkenswerte neuroprotektive Effekte und könnten daher auch beim Auftreten eines humanen Schlaganfalls entscheidende Vorteile bringen. Der präventive therapeutische Einsatz von Bilobalid oder Triheptanoin sollte daher in klinischen Studien weiter verfolgt werden.
The Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) here presents its updated recommendations for the treatment of documented fungal infections. Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. In recent years, new antifungal agents have been licensed, and agents already approved have been studied in new indications. The choice of the most appropriate antifungal treatment depends on the fungal species suspected or identified, the patient’s risk factors (e.g., length and depth of neutropenia), and the expected side effects. This guideline reviews the clinical studies that served as a basis for the following recommendations. All recommendations including the levels of evidence are summarized in tables to give the reader rapid access to the information.
Neurons which lose part of their input respond with a compensatory increase in excitatory synaptic strength. This observation is of particular interest in the context of neurological diseases, which are accompanied by the loss of neurons and subsequent denervation of connected brain regions. However, while the cellular and molecular mechanisms of pharmacologically induced homeostatic synaptic plasticity have been identified to a certain degree, denervation-induced homeostatic synaptic plasticity remains not well understood. Here, we employed the entorhinal denervation in vitro model to study the role of tumor necrosis factor alpha (TNFα) on changes in excitatory synaptic strength of mouse dentate granule cells following partial deafferentation. Our experiments disclose that TNFα is required for the maintenance of a compensatory increase in excitatory synaptic strength at 3–4 days post lesion (dpl), but not for the induction of synaptic scaling at 1–2 dpl. Furthermore, laser capture microdissection combined with quantitative PCR demonstrates an increase in TNFα-mRNA levels in the denervated zone, which is consistent with our previous finding on a local, i.e., layer-specific increase in excitatory synaptic strength at 3–4 dpl. Immunostainings for the glial fibrillary acidic protein and TNFα suggest that astrocytes are a source of TNFα in our experimental setting. We conclude that TNFα-signaling is a major regulatory system that aims at maintaining the homeostatic synaptic response of denervated neurons.